A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 707 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR EMA Recommends Extension of Indications for Nivolumab and Ipilimumab September 25, 2020 Does Sugar Feed Cancer? March 19, 2021 Research shows one size doesn’t fit all for cervical screening in... May 17, 2021 Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 Load more HOT NEWS ΤΙ ΕΙΝΑΙ Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ
